CD69 and neoplasm: To elucidate the underlying mechanisms associated with the improved therapeutic outcomes of DTIC/Epacasome-2, we then systemically investigated the NKG2D+(receptor), CD69+, IFN-γ+, Granzyme B+ or perforin+ NK and CD8+ T cells respectively, in tumours using flow cytometry.